Portfolio & Pipeline Strategy
How can we develop and commercialise immunotherapies faster than our competitors?
Driven by an internal perception of a conservative approach to clinical development, our client sought to dissect the case history of four high-profile products that demonstrated remarkably rapid regulatory approval timelines.
Eradigm’s detailed assessment of this complex question provided extensive learnings, enabling our client to drive multiple cross-functional workstreams to rethink their approach and decision-making for more dynamic clinical development.
< Previous Case Study
Next Case Study >